What is it about?

MDS patients have a very different prognosis, something usually calculated by the International Prognostic Scoring System revised (IPSS-R), that takes into account the presence and type of underlying genetic abnormalities, the proportion of bone marrow blasts as well as the number and depth of PB cytopenia. But this happens in a whole individual with his/her own personal life story before MDS diagnosis and this fact has been somehow neglected.

Featured Image

Why is it important?

The Spanish MDS Group (Grupo Español de Síndromes Mielodisplásicos, GESMD) has found that the prognostic impact of patient condition overrides that of mutational analysis for survival prediction, while mutational analysis was the most relevant when predicting leukemic transformation. This paper highlights the importance of considering the whole individual when facing an older adult with MDS.

Read the Original

This page is a summary of: Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group, American Journal of Hematology, July 2017, Wiley,
DOI: 10.1002/ajh.24813.
You can read the full text:

Read

Contributors

The following have contributed to this page